BRCA2 and cancer: This study primarily relies on isogeneic cell line pairs as models, which may not fully translate into in vivo systems or reflect the complexity of human tumors, limiting the ability to assess the physiological relevance, toxicity and therapeutic potential of targeting the 9-1-1 complex in BRCA2-deficient cancers.